M
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Price:
27.84 CNY
2.5%
Market Closed
Updated:
May 4, 2024
Mayinglong Pharmaceutical Group Co Ltd
Cost of Revenue
|
Mayinglong Pharmaceutical Group Co Ltd
Cost of Revenue Peer Comparison
Comparables:
H
3692
600436
600276
000538
C
300765
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
M
|
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
|
Cost of Revenue
-¥1.7B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cost of Revenue
-¥1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Cost of Revenue
-¥5.3B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-24%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cost of Revenue
-¥3.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-12%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cost of Revenue
-¥28.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-10%
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Cost of Revenue
-¥1.4B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
See Also
What is Mayinglong Pharmaceutical Group Co Ltd's Cost of Revenue?
Cost of Revenue
-1.7B
CNY
-1.7B
CNY
Based on the financial report for Sep 30, 2023, Mayinglong Pharmaceutical Group Co Ltd's Cost of Revenue amounts to -1.7B CNY.
What is Mayinglong Pharmaceutical Group Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-7%
-7%
Over the last year, the Cost of Revenue growth was 22%. The average annual Cost of Revenue growth rates for Mayinglong Pharmaceutical Group Co Ltd have been -6% over the past three years , -8% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet
